Low-dosage treatment in de novo XXXX with @entity191 : a prospective study.

@entity1 @entity2847 @entity2003 @entity910 @entity191 @entity2845 @entity1726 @entity18362
In 68 younger de novo @entity1 with the @entity2003 the action of @entity2847 , Sinemet, a combination of these drugs, and @entity18362 with additional @entity2847 or Sinemet medication was investigated over at least a 6-year period. The favorable reaction on Sinemet medication was complicated by the occurrence of @entity910 in the majority of cases as contrasted with the @entity2847 group. @entity910 were mild and not prominent in the combined group. In the sixth year, it appeared necessary to increase the dosage in the first three groups. Temporary complete replacement after 5 years of Sinemet by @entity2847 caused a clinical deterioration, whereas the @entity910 did not (completely) disappear. Both drugs markedly improved the @entity2845 in the @entity18362 group. The results in the old-age category (60 @entity1 ) without high vascular risk were comparable with those of the young @entity1 . The same applied for those @entity1726 @entity1 with high vascular risk, in whom the cerebral circulation could be restored. The final conclusion of this study can be formulated as follows: Primary multitherapy with low dosage @entity2847 and a levodopa preparation may be the therapy of choice. In case of high vascular risk, improvement of the cerebral circulation may be as important as treatment with anti- @entity191 drugs.
